Literature DB >> 8034208

Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study.

S Binder1, M Bonnet, M Velikay, J P Gerard, U Stolba, A Wedrich, H Hohenberg.   

Abstract

In a prospective study of the effect of postoperative radiation therapy for the prevention of reproliferation of membranes and recurrent proliferative vitreoretinopathy (PVR) two similar groups of patients with retinal detachment and PVR grade D1 to D3 in one eye were compared. Half the eyes (30) received a total dose of 3000 cGy after surgery; the other half remained untreated. After a follow-up of 6 months and 14 months or more (maximum 36 months) the anatomical and functional results of each group were compared. After 6 months in the unirradiated group 57% (17/30) remained attached and 43% (13/30) had detached again. In the irradiated group 63% (19/30) were attached and 37% (11/30) had detached. However, there was no statistically significant difference between the two groups (P = 0.479, Fisher's Exact Test). After 14 months the number of cured and uncured eyes remained the same in the unirradiated group, while in four of the eyes in the irradiated group a later onset of reproliferation and detachment occurred (after 7, 8, 12 and 14 months, respectively). A final cure rate of 57% (17/30) was achieved in the unirradiated group and a 50% (15/30) cure rate in the irradiated group. Thus the failure rate was 43% (13/30) in the unirradiated group and 50% (15/30) in the irradiated group (P = 0.473, Fisher's Exact Test). No side effects from the radiation were observed in any case and no radiation retinopathy occurred during an observation period of up to 3 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8034208     DOI: 10.1007/bf00184007

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  11 in total

1.  Suppression of experimental tractional retinal detachment by low-dose radiation therapy.

Authors:  T A Meredith; L Ficker; R Stevens; Z Olkowski; M Anderson; J Hartmann; I Crocker
Journal:  Arch Ophthalmol       Date:  1988-05

2.  Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation).

Authors:  R Machemer; H Laqua
Journal:  Am J Ophthalmol       Date:  1975-07       Impact factor: 5.258

3.  Experimental Fibroplasia in the rabbit vitreous. Retinal detachment induced by autologous fibroblasts.

Authors:  P Algvere; E Kock
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1976-05-26

4.  Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.

Authors:  Y Tano; D Chandler; R Machemer
Journal:  Am J Ophthalmol       Date:  1980-12       Impact factor: 5.258

5.  The classification of retinal detachment with proliferative vitreoretinopathy.

Authors: 
Journal:  Ophthalmology       Date:  1983-02       Impact factor: 12.079

6.  Inhibition of experimental intraocular proliferation with intravitreal 5-fluouracil.

Authors:  S Binder; B Riss; C Skorpik; W Kulnig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

7.  Inhibition of experimental intraocular proliferation with intravitreous 5-fluouracil. A transmission electron-microscopic study in rabbits.

Authors:  W Kulnig; S Binder; B Riss; C Skorpik
Journal:  Ophthalmologica       Date:  1984       Impact factor: 3.250

Review 8.  [Clinical and experimental results in the treatment of massive periretinal proliferation (MPP), a retinal detachment with a most unfavorable prognosis].

Authors:  S Binder
Journal:  Wien Klin Wochenschr Suppl       Date:  1982

9.  Radiation therapy for Graves' disease.

Authors:  M W Brennan; C R Leone; L Janaki
Journal:  Am J Ophthalmol       Date:  1983-08       Impact factor: 5.258

10.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

View more
  5 in total

Review 1.  Strategies to influence PVR development.

Authors:  Bernd Kirchhof
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08-10       Impact factor: 3.117

Review 2.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

Review 3.  Proliferative vitreoretinopathy.

Authors:  P K Leaver
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

4.  Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin E.

Authors:  Ying Wang; Zhigang Yuan; Caiyun You; Jindong Han; Haiyan Li; Zhuhong Zhang; Hua Yan
Journal:  BMC Ophthalmol       Date:  2014-11-25       Impact factor: 2.209

5.  Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial.

Authors:  Philip J Banerjee; Catey Bunce; David G Charteris
Journal:  Trials       Date:  2013-10-28       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.